Comparison
Leuprorelin vs. Bremelanotide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
53714-56-0
189691-06-3
Molecular weight
1209.4 g/mol
1025.18 g/mol
Half-life
3 h
2.7 h
Sequence
Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtAc-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHMechanism of action
Leuprorelin
Leuprorelin is a GnRH-receptor agonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
5
of which in humans
4
5
Effects recorded
4
3
Open conflicts
1
1
Documented adverse events
3
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Leuprorelin and Bremelanotide?
- Leuprorelin is classified as "Research other", while Bremelanotide is classified as "Research other". Leuprorelin: Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Leuprorelin or Bremelanotide?
- The highest available evidence level is "Human RCT" for Leuprorelin and "Human RCT" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Leuprorelin and Bremelanotide in Germany and the United States?
- Germany: Leuprorelin — Prescription, Bremelanotide — Unapproved. United States: Leuprorelin — Prescription, Bremelanotide — Prescription. These are factual summaries with source and review date on the individual pages.